Drug Metabolism and Pharmacokinetics最新文献_第2页

Intestinal secretion is potentially an important clearance mechanism for highly plasma-bound and low metabolic clearance efflux substrates 肠道分泌可能是高血浆结合和低代谢清除外排底物的重要清除机制

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101149

Murali Subramanian, Deepak Ahire, Rakshit Tanna, Josh Yu, Kelly Wang, Wei Wang, Gillian Smith, Xingrong Liu

引用次数: 0

Identification of physiological factors suppressing colonic drug absorption using quantum imaging technology 利用量子成像技术鉴定抑制结肠药物吸收的生理因素

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101141

Yugo Yasugi , Maho Hirosaki , Kazuki Hotta , Yumi Kato , Yasuyuki Ueda , Mayumi Iwatake , Hiroshi Yukawa , Ikumi Tamai , Yoshiyuki Shirasaka

引用次数: 0

Mitigating strategy for drug induced liver injury LED by reactive metabolites 反应性代谢物对药物性肝损伤的缓解策略

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101065

Sean Zhu

引用次数: 0

Unraveling cannabinoids-drug interactions in aging: Insights from PBPK modeling 揭示大麻素-药物在衰老中的相互作用：来自PBPK模型的见解

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101110

Zhu Zhou

引用次数: 0

TOC TOC

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/S1347-4367(25)00438-0

引用次数: 0

Gastrointestinal imaging with MRI: Insights into the behavior of dosage forms and the conditions at the site of drug release 胃肠道成像与MRI：洞察剂量形式的行为和药物释放部位的条件

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101069

Werner Weitschies

引用次数: 0

Human aldo-keto reductase (AKR) 1C1 and 1C2 act as coactivators of pregnane X receptor, a master regulator of drug-metabolizing and gluconeogenesis enzymes 人醛酮还原酶（AKR） 1C1和1C2是孕激素X受体的共激活因子，是药物代谢和糖异生酶的主要调节因子

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101481

Rei Mitamura , Seiya Takemoto , Yuka Aoyama , Koki Morita , Yuichiro Higuchi , Shotaro Uehara , Nao Yoneda , Hiroshi Suemizu , Tatsuki Fukami , Masataka Nakano , Miki Nakajima

{"title":"Human aldo-keto reductase (AKR) 1C1 and 1C2 act as coactivators of pregnane X receptor, a master regulator of drug-metabolizing and gluconeogenesis enzymes","authors":"Rei Mitamura , Seiya Takemoto , Yuka Aoyama , Koki Morita , Yuichiro Higuchi , Shotaro Uehara , Nao Yoneda , Hiroshi Suemizu , Tatsuki Fukami , Masataka Nakano , Miki Nakajima","doi":"10.1016/j.dmpk.2025.101481","DOIUrl":"10.1016/j.dmpk.2025.101481","url":null,"abstract":"<div><div>The aldo-keto reductase (AKR) 1C subfamily, comprising AKR1C1-1C4, plays a crucial role in drug metabolism and hormone biosynthesis. Recent studies have identified AKR1C3 as a co-activator of the androgen receptor. This study aimed to investigate whether AKR1Cs function as regulators of the pregnane X receptor (PXR), a member of the nuclear receptor superfamily, which upregulates drug-metabolizing enzymes such as cytochrome P450 (CYP) 3A4. Rifampicin-activated CYP3A4 induction was attenuated by AKR1C1/1C2 knockdown in ShP51 cells (PXR-overexpressing HepG2 cells), HepaRG cells, and HepaSH cells (hepatocytes from humanized liver mice). Co-immunoprecipitation analysis revealed that AKR1Cs interact with PXR. Immunofluorescent staining revealed that AKR1Cs are translocated into the nucleus with PXR by rifampicin in HepaRG cells. These results suggested that AKR1C1/1C2 has an ability to enhance transactivity of PXR. Consistent with the results of knockdown experiments, PXR-mediated CYP3A4 induction was significantly attenuated by treatment with AKR1C1/1C2 inhibitors, diazepam or flunitrazepam, in ShP51, HepaRG, and HepaSH cells. Furthermore, the induction of CYP2B6, CYP2C9, glucose 6-phosphatase, and phosphoenolpyruvate carboxykinase 1, all regulated by PXR, was attenuated by AKR1C1/1C2 inhibitors. Collectively, we demonstrated that AKR1C1/1C2 upregulates PXR transactivation. Clinically used drugs that inhibit AKR1C1/1C2 may suppress PXR-mediated transactivation of genes encoding drug-metabolizing and gluconeogenesis enzymes.</div></div>","PeriodicalId":11298,"journal":{"name":"Drug Metabolism and Pharmacokinetics","volume":"62 ","pages":"Article 101481"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144212336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utilizing PBPK modeling and in vitro data for predicting complex DDIS of OATP1B and CYP substrates caused by various perpetrators 利用PBPK模型和体外数据预测多种作案者引起的OATP1B和CYP底物的复杂DDIS

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101082

Yuichi Sugiyama

引用次数: 0

Assessment of ADME and DDI for LNP-MRNA therapeutics 评估ADME和DDI对LNP-MRNA治疗的影响

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101084

Lei Ci

引用次数: 0

Improving ADME properties of therapeutic antibodies by novel engineering technologies 利用新的工程技术改善治疗性抗体的ADME特性